Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-8,200
Closed -$2.19M 254
2022
Q3
$2.19M Buy
8,200
+3,900
+91% +$828K 0.08% 328
2022
Q2
$877K Sell
4,300
-1,100
-20% -$225K 0.03% 565
2022
Q1
$1.14M Buy
5,400
+3,500
+184% +$761K 0.04% 467
2021
Q4
$456K Sell
1,900
-9,100
-83% -$2.34M 0.02% 793
2021
Q3
$3.11M Buy
11,000
+1,600
+17% +$524K 0.1% 265
2021
Q2
$3.25M Buy
+9,400
New +$2.85M 0.11% 238

Other funds holding BIIB

Point72 Hong Kong's BIIB Position: Q3 2025 in Review

Point72 Hong Kong sold out of Biogen (BIIB) in Q3 2025, closing a stake of 11,083 shares — an estimated $1.39M sold.

Point72 Hong Kong first reported a position in BIIB in Q4 2014 and held it in 25 quarters. The position peaked at $6.33M in Q3 2021. 906 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

  • Point72 Hong Kong reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 11,083 Biogen shares in Q3 2025, an estimated $1.39M.
  • Point72 Hong Kong first reported a position in Biogen in Q4 2014 and held it in 25 quarters.
  • Point72 Hong Kong's Biogen position peaked at $6.33M in Q3 2021.
  • 906 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.